RxDoctor Payments DataLook up a doctor →

Samuel Lederman, MD

Obstetrics & Gynecology · Lake Worth, FLNPI 1124131230

Payments from drug & device makers

$13,409,214in general payments, 2019–2025

Across 1,210 payments — averaging $11,082 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$6.4M
  • Eli Lilly$2.3M
  • Ventana Medical Systems, Inc.$567K
  • Roche Molecular Systems, Inc.$481K
  • GSK$469K
  • Abbott$376K
  • plus $2.8M from 54 others
$111,981in research payments, 2019–2025

Across 12 payments — averaging $9331.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$84K
  • Eli Lilly$28K

What the payments were for

  • Consulting fees$6001%
  • Speaking & faculty fees$37,99279%
  • Travel & lodging$2,6225%
  • Food & beverage$6,53314%
  • Education$1410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC89$6,400,579
Eli Lilly5$2,325,429
Ventana Medical Systems, Inc.22$566,914
Roche Molecular Systems, Inc.70$481,355
GSK31$468,916
Abbott22$376,060
Gen-probe, Inc.9$336,148
Astellas Pharma Global Development100$316,815
AbbVie(2 entities)194$228,037
Exeltis, USA Inc.57$196,915
Sumitomo Pharma America, Inc.89$164,636
Amgen9$147,227
Eisai Inc.47$143,648
Organon22$129,874
Mylan Inc.31$125,872
BD2$112,621
Sebela Women's Health Inc.65$106,236
Johnson & Johnson16$100,195
Mylan Technologies Inc.8$79,658
Novo Nordisk AS14$77,084
Sebela Pharmaceuticals Inc.13$64,054
AstraZeneca7$60,497
Ironwood Pharmaceuticals, Inc10$37,690
Pfizer32$37,420
AMAG Pharmaceuticals, Inc.9$36,812
Myovant Sciences GmbH12$35,470
Mitsubishi Tanabe Pharma Development America, Inc.4$31,044
Dexcom, Inc.6$30,000
Astrazeneca UK Limited2$29,083
Currax Pharmaceuticals LLC6$29,041
Esperion Therapeutics, Inc.37$20,668
Alnylam Pharmaceuticals Inc.13$20,343
Novartis1$18,405
Amarin Pharma, Inc.1$18,185
Modernatx, Inc.6$17,555
Astellas Pharma US Inc33$17,524
Bayer20$10,514
Scynexis, Inc.3$4,187
Merck4$3,976
Aspira Women's Health Inc2$600
Mayne Pharma Commercial LLC20$312
Gynesonics, Inc.2$233
Hologic Sales And Service, LLC9$197
Myriad Women's Health, Inc.1$155
Myovant Sciences Inc.9$141
Therapeuticsmd, Inc.9$130
Exact Sciences4$113
Coopersurgical, Inc.5$77
Evofem Biosciences, Inc.3$55
LSI Solutions Inc1$51
Roche Diagnostics Corporation1$46
Mylan Pharmaceuticals Inc.2$40
Avion Pharmaceuticals3$40
Smith+Nephew1$37
Kowa Pharmaceuticals America, Inc.2$37
Biogen1$30
Shield Therapeutics Inc1$28
Lupin Inc.2$27
Kvk-tech, Inc.3$26
Fujifilm New Development USA, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,409,214 in reported general payments places this provider in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.

See all obstetrics & gynecology providers in Florida

Medicare billing

Part B allowed, 2024
$36,853
Medicare patients
184
Services billed
542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol229$13,586
MyrbetriqMirabegron24$13,255
Estradiol (Twice Weekly)Estradiol28$1,684
ProgesteroneProgesterone, Micronized52$1,290
ValacyclovirValacyclovir Hcl37$1,236
Raloxifene Hcl27$949
Terconazole19$450
Acyclovir17$390
Betamethasone Dipropionate11$286
Medroxyprogesterone Acetate16$250
Clobetasol Propionate15$217
Blisovi FeNorethindrone-E.Estradiol-Iron14$194
MicrogestinNorethindrone Ac/Eth Estradiol17$181
Fluconazole17$138
Alendronate Sodium27$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$17,524$13,25524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.

Other obstetrics & gynecology in Lake Worth

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →